Informace o publikaci

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Autoři

BALIAKAS P. MATTSSON M. HADZIDIMITRIOU A. MINGA E. AGATHANGELIDIS A. SUTTON L.A. SCARFO L. DAVIS Z. YAN X.J. PLEVOVÁ Karla SANDBERG Y. VOJDEMAN F.J. TZENOU T. CHU C.C. VERONESE S. MANSOURI L. SMEDBY K.E. GIUDICELLI V. NGUYEN-KHAC F. PANAGIOTIDIS P. JULIUSSON G. ANAGNOSTOPOULOS A. LEFRANC M.P. TRENTIN L. CATHERWOOD M. MONTILLO M. NIEMANN C.U. LANGERAK A.W. POSPÍŠILOVÁ Šárka STAVROYIANNI N. CHIORAZZI N. OSCIER D. JELINEK D.F. SHANAFELT T. DARZENTAS Nikos BELESSI C. DAVI F. GHIA P. ROSENQUIST R. STAMATOPOULOS K.

Rok publikování 2018
Druh Článek v odborném periodiku
Časopis / Zdroj haematologica
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://www.haematologica.org/content/haematol/early/2017/12/18/haematol.2017.182634.full.pdf
Doi http://dx.doi.org/10.3324/haematol.2017.182634
Klíčová slova CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; CHEMOIMMUNOTHERAPY; TRIAL
Popis The overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) has improved over the last decades mainly due to advances in the understanding of the disease biology and the introduction of novel therapeutic approaches(1). In the present retrospective study we investigated trends in OS in subgroups of cases defined by genetic and immunogenetic features aiming at addressing the question whether advances in chemoimmunotherapy had a uniform impact across all CLL patients. We found that such advances have translated into prolonged OS in all prognostic subgroups examined except those carrying TP53 abnormalities, as expected, but also those assigned to stereotyped subsets #1 and #2, that are generally devoid of such gene aberrations. This latter finding, reported here for the first time, indicates the need for alternative treatment options for these patients.
Související projekty: